Clinical application of monoclonal antibodies in targeted therapy

Skrócona strona pozycji
dc.contributor.authorSuperson, Maciej
dc.contributor.authorSzmyt, Katarzyna
dc.contributor.authorSzymańska, Katarzyna
dc.contributor.authorWalczak, Kamil
dc.contributor.authorWnorowski, Jeremi
dc.contributor.authorZarębski, Łukasz
dc.date.accessioned2020-01-21T13:56:06Z
dc.date.available2020-01-21T13:56:06Z
dc.date.issued2019
dc.description.abstractIntroduction. Recently, monoclonal antibodies (mAbs) have become powerful human therapeutics in the diagnosis and treatment of many diseases. Drugs based on mAbs are approved for the treatment of cardiovascular, respiratory, hematology, autoimmunology, and oncology diseases. Aim. To present the current state of knowledge about the application of mAbs in the therapy of various diseases such as cancer, autoimmune and Alzheimer’s diseases. Material and methods. We conducted a thorough review of the scientific literature from the following databases: EBSCO, PubMed, Science Direct, and Springer Link. Results. Currently, the Food and Drug Administration (FDA) has approved more than 50 therapeutic mAbs which are applied in various clinical trials. Action of mAb are based on various mechanisms, including directly targeting the cells, modifying the host response, recognizing and degrading molecules as well as delivering cytotoxic moieties. Conclusion. Despite some limitations including side effects, and therapeutic challenges, monoclonal antibodies are an attractive option for the development of new therapies and molecular drug targets against a wide range of common diseases due to their specificity and flexibility. MAbs are considered as a great hope for medicine, and effective and safe drugs in the treatment of various diseases.pl_PL.UTF-8
dc.identifier.citationEuropean Journal of Clinical and Experimental Medicine T. 17, z. 4 (2019), s. 338–346pl_PL.UTF-8
dc.identifier.doi10.15584/ejcem.2019.4.9
dc.identifier.eissn2544-1361
dc.identifier.issn2544-2406
dc.identifier.urihttp://repozytorium.ur.edu.pl/handle/item/5183
dc.language.isoengpl_PL.UTF-8
dc.publisherWydawnictwo Uniwersytetu Rzeszowskiegopl_PL.UTF-8
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Międzynarodowe*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectcancerpl_PL.UTF-8
dc.subjectinflammatory bowel diseasespl_PL.UTF-8
dc.subjectAlzheimer’s diseasepl_PL.UTF-8
dc.subjectimmunotherapypl_PL.UTF-8
dc.subjecttargeted therapypl_PL.UTF-8
dc.titleClinical application of monoclonal antibodies in targeted therapypl_PL.UTF-8
dc.typereportpl_PL.UTF-8
Pliki
Oryginalny pakiet
Aktualnie wyświetlane 1 - 1 z 1
Obrazek miniatury
Nazwa:
9 superson-clinical application.pdf
Rozmiar:
214.59 KB
Format:
Adobe Portable Document Format
Opis:
Pobierz
Pakiet licencji
Aktualnie wyświetlane 1 - 1 z 1
Obrazek miniatury
Nazwa:
license.txt
Rozmiar:
1.22 KB
Format:
Item-specific license agreed upon to submission
Opis:
Pobierz
Kolekcje
European Journal of Clinical and Experimental Medicine T.17, z. 4 (2019)